カテゴリ： Transparency Market Research, 世界, 医療/バイオ

小細胞肺がん（SCLC）治療薬の世界市場（2022～2031）：治療種類別

■ 英語タイトル：Small Cell Lung Cancer [SCLC] Therapeutics Market (Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

調査会社Transparency Market Research社が発行したリサーチレポート（データ管理コード：TMR23AP147）■ 発行会社/調査会社：Transparency Market Research
■ 商品コード：TMR23AP147
■ 発行日：2023年1月24日
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：160
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧）USD5,795 ⇒換算￥880,840見積依頼/購入/質問フォーム
Multi User（5名様閲覧）USD8,795 ⇒換算￥1,336,840見積依頼/購入/質問フォーム
Corporate License（法人閲覧）USD11,795 ⇒換算￥1,792,840見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Transparency Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[小細胞肺がん（SCLC）治療薬の世界市場（2022～2031）：治療種類別]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Transparency Market Research社の本調査レポートでは、小細胞肺がん（SCLC）治療薬の世界市場について総合的に分析し、今後の市場動向を予測しています。本書は、序論、仮定＆調査手法、エグゼクティブサマリー、市場概要、キーインサイト、治療種類別（化学療法、標的療法、免疫療法、その他）分析、エンドユーザー別（病院、がん治療センター、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの項目が整理されています。また、本書内には、ZIOPHARM Oncology、GlaxoSmithKline、Menarini、Bristol-Myers Squibb、Sanofi、Novartis AG、Elekta AB、Siemens Healthcare GmbH、G1 Therapeuticsなどの企業情報が含まれています。
・序論
・仮定＆調査手法
・エグゼクティブサマリー
・市場概要
・キーインサイト
・世界の小細胞肺がん（SCLC）治療薬市場規模：治療種類別
- 化学療法の市場規模
- 標的療法の市場規模
- 免疫療法の市場規模
- その他治療種類の市場規模
・世界の小細胞肺がん（SCLC）治療薬市場規模：エンドユーザー別
- 病院における市場規模
- がん治療センタにおける市場規模
- その他エンドユーザーにおける市場規模
・世界の小細胞肺がん（SCLC）治療薬市場規模：地域別
- 北米の小細胞肺がん（SCLC）治療薬市場規模
- ヨーロッパの小細胞肺がん（SCLC）治療薬市場規模
- アジア太平洋の小細胞肺がん（SCLC）治療薬市場規模
- 中南米のアルミニウムスラグ市場規模
- 中東・アフリカのアルミニウムスラグ市場規模
・競争状況

Small Cell Lung Cancer [SCLC] Therapeutics Market – Scope of Report
TMR’s report on the global small cell lung cancer [SCLC] therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global small cell lung cancer [SCLC] therapeutics market for the period 2017–2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global small cell lung cancer [SCLC] therapeutics market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the small cell lung cancer [SCLC] therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global small cell lung cancer [SCLC] therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global small cell lung cancer [SCLC] therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global small cell lung cancer [SCLC] therapeutics market.

The report delves into the competitive landscape of the global small cell lung cancer [SCLC] therapeutics market. Key players operating in the global small cell lung cancer [SCLC] therapeutics market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global small cell lung cancer [SCLC] therapeutics market profiled in this report.

RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market small cell lung cancer [SCLC] therapeutics.

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

• Industry Sources:
o WorldWideScience.org
o Elsevier, Inc.
o National Institutes of Health (NIH)
o PubMed
o NCBI
o Department of Health Care Service
• Trade Data Sources
o Trade Map
o UN Comtrade
o Trade Atlas
• Company Information
o OneSource Business Browser
o Hoover’s
o Factiva
o Bloomberg
• Mergers & Acquisitions
o Thomson Mergers & Acquisitions
o MergerStat
o Profound

Primary Research

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:

Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:

Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.

Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Small Cell Lung Cancer (SCLC) Therapeutics Market
4. Market Overview
    4.1. Introduction
        4.1.1. Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, 2017–2031
5. Key Insights
    5.1. Technological Advancements
    5.2. Pipeline Analysis
    5.3. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by Therapy Type
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Therapy Type, 2017–2031
        6.3.1. Chemotherapy
        6.3.2. Targeted Therapy
        6.3.3. Immunotherapy
        6.3.4. Others
    6.4. Market Attractiveness Analysis, by Therapy Type
7. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by End-user
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by End-user, 2017–2031
        7.3.1. Hospitals
        7.3.2. Cancer Therapy Centers
        7.3.3. Others (Specialty Clinics)
    7.4. Market Attractiveness Analysis, by End-user
8. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by Region
    8.1. Key Findings
    8.2. Market Value Forecast, by Region
        8.2.1. North America
        8.2.2. Europe
        8.2.3. Asia Pacific
        8.2.4. Latin America
        8.2.5. Middle East & Africa
    8.3. Market Attractiveness Analysis, by Region
9. North America Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast
    9.1. Introduction
        9.1.1. Key Findings
    9.2. Market Value Forecast, by Therapy Type, 2017–2031
        9.2.1. Chemotherapy
        9.2.2. Targeted Therapy
        9.2.3. Immunotherapy
        9.2.4. Others
    9.3. Market Value Forecast, by End-user, 2017–2031
        9.3.1. Hospitals
        9.3.2. Cancer Therapy Centers
        9.3.3. Others (Specialty Clinics)
    9.4. Market Value Forecast, by Country, 2017–2031
        9.4.1. U.S.
        9.4.2. Canada
    9.5. Market Attractiveness Analysis
        9.5.1. By Therapy Type
        9.5.2. By End-user
        9.5.3. By Country
10. Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by Therapy Type, 2017–2031
        10.2.1. Chemotherapy
        10.2.2. Targeted Therapy
        10.2.3. Immunotherapy
        10.2.4. Others
    10.3. Market Value Forecast, by End-user, 2017–2031
        10.3.1. Hospitals
        10.3.2. Cancer Therapy Centers
        10.3.3. Others (Specialty Clinics)
    10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
        10.4.1. Germany
        10.4.2. U.K.
        10.4.3. France
        10.4.4. Italy
        10.4.5. Spain
        10.4.6. Rest of Europe
    10.5. Market Attractiveness Analysis
        10.5.1. By Therapy Type
        10.5.2. By End-user
        10.5.3. By Country/Sub-region
11. Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Therapy Type, 2017–2031
        11.2.1. Chemotherapy
        11.2.2. Targeted Therapy
        11.2.3. Immunotherapy
        11.2.4. Others
    11.3. Market Value Forecast, by End-user, 2017–2031
        11.3.1. Hospitals
        11.3.2. Cancer Therapy Centers
        11.3.3. Others (Specialty Clinics)
    11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
        11.4.1. China
        11.4.2. Japan
        11.4.3. India
        11.4.4. Australia & New Zealand
        11.4.5. Rest of Asia Pacific
    11.5. Market Attractiveness Analysis
        11.5.1. By Therapy Type
        11.5.2. By End-user
        11.5.3. By Country/Sub-region
12. Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Therapy Type, 2017–2031
        12.2.1. Chemotherapy
        12.2.2. Targeted Therapy
        12.2.3. Immunotherapy
        12.2.4. Others
    12.3. Market Value Forecast, by End-user, 2017–2031
        12.3.1. Hospitals
        12.3.2. Cancer Therapy Centers
        12.3.3. Others (Specialty Clinics)
    12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
        12.4.1. Brazil
        12.4.2. Mexico
        12.4.3. Rest of Latin America
    12.5. Market Attractiveness Analysis
        12.5.1. By Therapy Type
        12.5.2. By End-user
        12.5.3. By Country/Sub-region
13. Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Therapy Type, 2017–2031
        13.2.1. Chemotherapy
        13.2.2. Targeted Therapy
        13.2.3. Immunotherapy
        13.2.4. Others
    13.3. Market Value Forecast, by End-user, 2017–2031
        13.3.1. Hospitals
        13.3.2. Cancer Therapy Centers
        13.3.3. Others (Specialty Clinics)
    13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
        13.4.1. GCC Countries
        13.4.2. South Africa
        13.4.3. Rest of Middle East & Africa
    13.5. Market Attractiveness Analysis
        13.5.1. By Therapy Type
        13.5.2. By End-user
        13.5.3. By Country/Sub-region
14. Competition Landscape
    14.1. Market Player – Competition Matrix (by tier and size of companies)
    14.2. Market Share Analysis, by Company (2021)
    14.3. Company Profiles
        14.3.1. ZIOPHARM Oncology
            14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.1.2. Product Portfolio
            14.3.1.3. Financial Overview
            14.3.1.4. SWOT Analysis
            14.3.1.5. Strategic Overview
        14.3.2. GlaxoSmithKline
            14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.2.2. Product Portfolio
            14.3.2.3. Financial Overview
            14.3.2.4. SWOT Analysis
            14.3.2.5. Strategic Overview
        14.3.3. Menarini
            14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.3.2. Product Portfolio
            14.3.3.3. Financial Overview
            14.3.3.4. SWOT Analysis
            14.3.3.5. Strategic Overview
        14.3.4. Bristol-Myers Squibb
            14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.4.2. Product Portfolio
            14.3.4.3. Financial Overview
            14.3.4.4. SWOT Analysis
            14.3.4.5. Strategic Overview
        14.3.5. Sanofi
            14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.5.2. Product Portfolio
            14.3.5.3. Financial Overview
            14.3.5.4. SWOT Analysis
        14.3.6. Novartis AG
            14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.6.2. Product Portfolio
            14.3.6.3. Financial Overview
            14.3.6.4. SWOT Analysis
        14.3.7. Elekta AB
            14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.7.2. Product Portfolio
            14.3.7.3. Financial Overview
            14.3.7.4. SWOT Analysis
        14.3.8. Siemens Healthcare GmbH
            14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.8.2. Product Portfolio
            14.3.8.3. Financial Overview
            14.3.8.4. SWOT Analysis
        14.3.9. G1 Therapeutics
            14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.9.2. Product Portfolio
            14.3.9.3. Financial Overview
            14.3.9.4. SWOT Analysis

List of Tables

Table 01: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017–2031

Table 02: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 03: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 04: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017–2031

Table 05: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 06: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 07: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017–2031

Table 08: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 09: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017–2031

Table 11: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 12: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 13: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017–2031

Table 14: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 15: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 16: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017–2031

Table 17: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 18: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 小細胞肺がん（SCLC）治療薬の世界市場2023-2031：産業分析、規模、シェア、成長、動向、予測
  • 肺がん治療の世界市場（2022～2031）：治療種類別
  • カテーテル関連血流感染症の世界市場（2022～2031）：治療種類別
  • 痔瘻治療の世界市場2023～2031：治療種類別、適用別
  • 細胞・遺伝子療法製造の世界市場2023～2031：治療種類別、製品種類別
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(TMR23AP147 )"小細胞肺がん（SCLC）治療薬の世界市場（2022～2031）：治療種類別" (英文：Small Cell Lung Cancer [SCLC] Therapeutics Market (Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031)はTransparency Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。